CD274 and breast cancer: The IMpassion130 clinical trial demonstrated the benefit of atezolizumab plus nab-paclitaxel in the progression-free survival (PFS) and the overall survival (OS) of patients with locally advanced or metastatic triple-negative BC with programmed cell death ligand-1 (PD-L1) immune cell-positive (>1%) disease [6,7,8,9].